If your holiday shopping list includes a health-conscious someone who just has to have something unique, what could be more personal than an analysis of his or her genetic makeup?
The retail prices of 19 brand-name prescription dermatology medications have increased an average of more than 400% over the past six years, according to a study. Those findings are sure to add support to the growing public discord over the rising cost of drugs.
Doctors often prescribe expensive brand-name drugs even when generics would be cheaper and just as effective. Physicians should instead prescribe generics whenever possible, the American College of Physicians recommended this week.
Pharmacy benefits manager CVS Health has included Amgen's drug Repatha to its formulary. The drug is one of two in a new class of cholesterol-lowering medications. It's the latest in a series of moves made by PBMs to address the high costs of some newer, brand-name therapies.
When he retired from Baxter International after 25 years, David Jonas started a new company, PharMEDium Healthcare. It just sold for $2.58 billion.
The boards of Pfizer and Ireland's Allergan on Sunday approved a merger deal worth $160 billion. The deal would create the largest drugmaker by sales.
Generic versions of off-patent drugs, which today account for more than 88% of all prescriptions, save patients and the U.S. healthcare system hundreds of billions of dollars per year. That isn't turning out to be the case with biosimilars.
The measure, if passed, would require drugmakers to provide discounts to the state at the same rate as the U.S. Veterans Affairs Department, which is about 20%. Drugmakers have mobilized, donating $23 million since Nov. 3 to fight the ballot measure, according to state records.
Global use of prescription drugs shows no sign of slowing down over the next few years, according to a new report, which projects 4.5 trillion doses will be used in 2020, with China and India driving the spike in demand.
Medicaid regulations require that drug companies charge the state-federal health program for the poor the lowest or “best” price that they negotiate with any other buyer. In theory, the best-price requirement protects taxpayers from price-gouging. But the reality is a little different.
The American Medical Association's House of Delegates voted Tuesday to support a ban on direct-to-consumer drug and medical-device advertising, saying the ads drive up the demand for more expensive treatments.
Health policy discussions in the second Democratic presidential debate Saturday night illuminated differences in how former Secretary of State Hillary Clinton and Vermont Sen. Bernie Sanders would continue the aims of the Affordable Care Act.